# Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

> **NCT00301964** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Recurrent Endometrial Carcinoma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00301964
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301964, "Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00301964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*